Recent developments include the acquisition of Family Beginnings fertility clinic, expansion of fertility services including platelet-rich plasma therapy and telehealth, multiple reverse stock splits, and financial results reporting with strategic focus on core fertility operations.

• INVO Fertility completed the acquisition of Family Beginnings, an Indiana-based fertility clinic offering IVF and IVC, expanding its clinical footprint and supporting growth of its fertility services platform [S1].
• The company expanded fertility services with the introduction of platelet-rich plasma therapy at the Wisconsin Fertility Institute [N6].
• INVO Fertility expanded telehealth services to enhance access to expert fertility care in multiple states [N7].
• The company enhanced fertility services with expanded training and improved INVOcell pricing [N5].
• INVO Fertility reported Q1 2025 financial results and emphasized strategic focus on core fertility operations [N8].
• The company announced and implemented multiple reverse stock splits, including a 1-for-3 split effective July 21, 2025, and a 1-for-5 split effective March 27, 2026 [N4][S1].
• INVO Fertility shares surged following patent issuance for a modified INVOcell device [N1].
• The company experienced a share price increase of over 300% in early 2026 [N2].

INVO Fertility's acquisition strategy has rapidly expanded its clinic network and revenue base, transitioning it into a healthcare services company with positive cash flow potential. The proprietary INVOcell device offers a unique fertility treatment option that may appeal to patients and clinics seeking alternatives to traditional IVF. Recent expansions in telehealth and fertility therapies enhance service offerings and patient access. The company's ability to raise capital through private placements and warrant exercises supports its growth initiatives.

The company reported a significant net loss and has liquidity ratios indicating limited short-term financial flexibility as of the latest fiscal year. Multiple reverse stock splits suggest challenges in maintaining share price levels. The company faces risks related to regulatory compliance, as indicated by Nasdaq notices for late filings. Legal disputes related to acquisitions have required settlements. The fertility services market is competitive, and the company's financial position and execution risks may impact its operational stability.

INVO Fertility's moat is based on its proprietary INVOcell device, the first intravaginal culture technology with clinical outcomes comparable to traditional IVF, and its integrated clinic operations model. The combination of technology and clinic acquisitions provides a differentiated approach to fertility services. The company's strategy to acquire profitable clinics and expand its clinical footprint supports scale and positive cash flow, which may create barriers to entry for competitors. However, the fertility services market is competitive and subject to regulatory and reimbursement challenges.

• Financial Risk: The company reported a net loss of $23.32 million for the fiscal year ended December 31, 2025, with liquidity ratios (current ratio 0.27, cash ratio 0.19) indicating limited short-term financial flexibility.
• Regulatory and Compliance Risk: INVO Fertility received Nasdaq notices for late filing of its 10-K and 10-Q reports in 2026, requiring a plan to regain compliance, which poses risks to its listing status and investor confidence.
• Legal Risk: The company settled litigation related to the acquisition of Wisconsin Fertility Institute, involving a $6 million settlement payable over time, indicating potential acquisition-related legal liabilities.
• Market and Competitive Risk: The fertility services market is competitive with alternative technologies and providers; the company's success depends on adoption of its INVOcell device and clinic operations.

• INVO Fertility, Inc. is a healthcare services and technology company focused on the fertility marketplace, dedicated to expanding access to assisted reproductive technology (ART) care to patients in need.
• The company's principal commercial strategy is acquiring, establishing, and operating fertility clinics and related businesses and technologies, focusing on US-based profitable fertility clinics.
• As of the latest filing, INVO Fertility operates four fertility clinics in the United States.
• The clinics offer fertility services including in vitro fertilization (IVF) and intravaginal culture (IVC) enabled by the proprietary INVOcell medical device.
• INVOcell is a device that enables fertilization and early embryo development to occur in vivo within the woman's body, representing the first intravaginal culture technique of its kind, with pregnancy success and live birth rates equivalent to IVF.
• The company also sells and distributes the INVOcell device to third-party fertility clinics.
• INVO Fertility completed the acquisition of Family Beginnings, an Indiana-based fertility clinic offering IVF and IVC, on February 18, 2026.
• The acquisition of Family Beginnings expanded the company's clinical footprint and supports growth of its fertility services platform.
• INVO Fertility acquired the Wisconsin Fertility Institute (WFI) in August 2023, an established and profitable clinic that significantly increased the company's annual revenue and cash flow.
• The company has established joint ventures to open INVO Centers in Birmingham, Alabama, and Atlanta, Georgia, to increase use of INVOcell and expand clinic-based fertility operations.
• INVO Fertility has expanded its fertility services with the introduction of platelet-rich plasma therapy at the Wisconsin Fertility Institute and expanded telehealth services to enhance access to expert fertility care in multiple states.
• The company has implemented multiple reverse stock splits, including a 1-for-3 reverse stock split effective July 21, 2025, and a 1-for-5 reverse stock split effective March 27, 2026.
• INVO Fertility reported record revenue growth in Q4 2024 and full year 2024 financial results, and reported Q1 2025 financial results with a strategic focus on core fertility operations.
• Financial snapshot as of December 31, 2025: revenue of $6.84 million USD, net loss of $23.32 million USD, basic and diluted EPS of -214.64 USD per share.
• Liquidity ratios as of December 31, 2025, show current assets of $2.76 million USD, current liabilities of $10.33 million USD, current ratio of 0.27, and cash ratio of 0.19, indicating limited short-term liquidity.
• The company has engaged in financing transactions including convertible notes and private placements to support growth and liquidity needs.
• INVO Fertility received Nasdaq letters in 2026 for late filings of its 10-K and 10-Q reports but maintained its listing with a plan to regain compliance.